Hims & Hers is disrupting the weight loss market with a new generic pill. ➡️
Yaani, they are directly challenging Novo Nordisk. Competition for the obesity market is getting real.
Basically, an oral pill is much more convenient than weekly injections. It's a huge shift.
I mean, Hims is offering this at a fraction of the cost. More people can now afford treatment.
You know, they use compounded GLP-1 versions to bypass patents. It is legal but aggressive.
Investors are loving this move. Hims stock has seen a massive surge as market share grows.
Experts are still watching. Compounded pills must meet strict standards to ensure patient safety.
The weight loss war is just starting. Expect Novo Nordisk to respond with new $ strategies.
Finished with Hims? Read our previous $ report on the Washington Post leadership crisis.